1500 East Medical Center Drive
Ann Arbor, MI 48109
Available to mentor
Anna Suk-Fong Lok, M.D., is director of clinical hepatology and assistant dean for clinical research at the University of Michigan Medical School. She also is the Dame Sheila Sherlock Distinguished University Professor of Hepatology and Internal Medicine and Alice Lohrman Andrews Research Professor of Hepatology in the Department of Internal Medicine.
In her role as assistant dean, Dr. Lok is responsible for leading, championing, and implementing recommendations from the Research Board of Directors to transform the clinical trials enterprise of the academic medical center. She is responsible for the overall leadership and direction, management, and oversight of the Clinical Trials Support Units and the Clinical Research Unit, training of clinical investigators, and facilitation and support of clinical research.
Dr. Lok obtained her medical degree from the University of Hong Kong and her hepatology training under the late Dame Sheila Sherlock at the Royal Free Hospital in London, UK. She was on the faculty at the University of Hong Kong until she moved to the United States in 1992.
Her research focuses on the natural history and treatment of hepatitis B and C, and the prevention of liver cancer. Her research is funded by the National Institutes of Health, federal and private foundations, and various pharmaceutical companies. She has published more than 600 papers on viral hepatitis and liver diseases and is the co-author of five editions of the American Association for the Study of Liver Diseases Association Guidelines on Hepatitis B. She was one of the top 1% most cited scientists in the world for the decade 2002-12. She has trained more than 60 fellows and junior faculty from all over the world, some of whom have risen to the ranks of full professors and directors of liver programs in their home country. She received a Distinguished Mentor Award from the Michigan Institute of Clinical and Health Research in 2012, an Inspirational Physician Award from the American Medical Association in 2014, and a Distinguished Mentor Award from the American Gastroenterological Association in 2022. She was inducted into the Clinical Excellence Society in the Department of Internal Medicine in 2013.
Dr. Lok has received many awards throughout her career. She has been included in the list of “Best Doctors” and “Who's Who” for many years. She was inducted into the Association of American Physicians in 2012 and elected to the National Academy of Medicine in 2022. Recent awards include the Distinguished Scientist Award from the Hepatitis B Foundation in 2008, the Distinguished Women Scientist Award from the American Gastroenterological Association in 2008, the Distinguished Service Award from the American Association for the Study of Liver Diseases in 2011, the Distinguished Scientific Achievement Award from the American Liver Foundation in 2015, the William Beaumont Prize in Gastroenterology from the American Gastroenterological Association in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver and an honorary Doctor of Science degree from the University of Hong Kong in 2017, the International Recognition Award from the European Association of the Study of the Liver in 2018, and a Distinguished University Professorship from the University of Michigan in 2019.
She is currently an associate editor of Hepatology Communication. She was an associate editor of HEPATOLOGY from 2001-06, a co-editor of the Journal of Viral Hepatitis from 2007-09, and a senior associate editor of GASTROENTEROLOGY from 2011-12.
Dr. Lok was the President of the American Association for the Study of Liver Diseases in 2017.
-
MDUniversity of Hong Kong, Hong Kong, 1990
-
MB BSUniversity of Hong Kong School of Medicine, Hong Kong, 1977
-
Center MemberMM-PKUHSC Joint Institute
-
Center MemberRogel Cancer Center
-
Center MemberGlobal REACH
-
Center MemberInstitute for Healthcare Policy and Innovation
Epidemiology, natural history, and treatment of hepatitis B and C
Risk stratification of nonalcoholic fatty liver disease
Prevention and early detection of hepatocellular carcinoma
-
Terrault N, Lok AS. Gut, 2024 Nov 5;Journal ArticleQuest for HBV functional cure: what have we learnt from silencing RNAs?
DOI:10.1136/gutjnl-2024-333763 PMID: 39500554 -
Tapper EB, Saleh ZM, Nikirk S, Bajaj J, Chen X, Lok AS-F. J Clin Exp Hepatol, 2024 14 (6): 101439Journal ArticleMedically Tailored Meals for Patients With Cirrhosis and Hepatic Encephalopathy: The BRAINFOOD Proof-of-concept Trial.
DOI:10.1016/j.jceh.2024.101439 PMID: 38882178 -
Ghany MG, King WC, Hinerman AS, Lok ASF, Lisker-Melman M, Chung RT, Terrault N, Janssen HLA, Khalili M, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Hepatology, 2024 Nov 1; 80 (5): E82 - E84.Journal ArticleReply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB.
DOI:10.1097/HEP.0000000000000963 PMID: 38861678 -
Terrault NA, Sterling R, Lok AS, Ghany MG, Feld JJ, Cloherty G, Wahed AS, Yang X. J Infect Dis, 2024 Oct 30;Journal ArticleHBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
DOI:10.1093/infdis/jiae541 PMID: 39478672 -
Macgregor M, Mazumder N, Tapper E, Lok A. The American Journal of Gastroenterology, 2024 Oct; 119 (10S): s1230 - s1230.Journal ArticleS1687 Patients Have Poor One Year Outcomes After Requiring Large Volume Paracentesis
DOI:10.14309/01.ajg.0001036116.74759.6b -
Bloom PP, Fisher CJ, Tedesco N, Kamdar N, Garrido-Trevino L, Robin J, Asrani SK, Lok AS. Hepatology, 2024 Sep 12;Journal ArticleHEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy.
DOI:10.1097/HEP.0000000000001086 PMID: 39264936 -
Gairing SJ, Mangini C, Zarantonello L, Nielsen EJ, Danneberg S, Sultanik P, Galle PR, Gioia S, Labenz J, Lok A, Marquardt JU, Lauridsen M, Bloom P, Thabut D, Nardelli S, Montagnese S, Labenz C. Journal of Hepatology, 2024 Jun; 80: s214Journal ArticleFRI-075 The lower, the worse? Impact of PHES results on the risk of overt hepatic encephalopathy in patients with minimal hepatic encephalopathy
DOI:10.1016/s0168-8278(24)00860-2 -
Gairing SJ, Mangini C, Zarantonello L, Gioia S, Nielsen EJ, Danneberg S, Lok AS, Sultanik P, Galle PR, Labenz J, Thabut D, Marquardt JU, Bloom PP, Lauridsen MM, Montagnese S, Nardelli S, Labenz C. J Intern Med, 2024 Mar; 295 (3): 331 - 345.Journal ArticleMinimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival.
DOI:10.1111/joim.13747 PMID: 37983845